Welcome to our dedicated page for MVIR news (Ticker: MVIR), a resource for investors and traders seeking the latest updates and insights on MVIR stock.
Medivir AB (MVIR) delivers cutting-edge oncology solutions through targeted therapies and strategic collaborations. This news hub provides investors and medical professionals with essential updates on clinical trials, regulatory milestones, and partnership developments shaping the future of cancer treatment.
Access real-time information on Medivir's lead program fostrox for hepatocellular carcinoma, pediatric rare disease initiatives, and veterinary applications. Our curated news collection features verified updates on phase 2b trial preparations, partnership expansions, and scientific breakthroughs – all critical for informed decision-making in biotech investments.
Key content includes progress reports on liver-targeted chemotherapy trials, analysis of orphan drug designations, and updates on out-licensing agreements. Each update undergoes rigorous verification to ensure alignment with regulatory disclosures and clinical evidence standards.
Bookmark this page for consolidated access to Medivir's most impactful developments. Check regularly for updates on trial enrollment completions, peer-reviewed publications, and strategic moves in precision oncology.
Medivir AB announced that an abstract for the combination of fostrox + Lenvima in hepatocellular carcinoma (HCC) has been accepted for presentation at the European Society for Medical Oncology Gastrointestinal Cancers Congress. The abstract titled 'Liver pharmacodynamics in an open-label phase Ib/IIa study of fostrox in combination with lenvatinib in hepatocellular carcinoma' will be presented at the conference. The presentation will include pharmacodynamic data from patients in the ongoing clinical study, evaluating the impact on normal liver function and DNA damage in tumor cells vs healthy cells. It will also provide an update on efficacy endpoints as the study continues to mature. The poster will be available on Medivir's website after the presentation.
